Skip to main content
SpringerLink
Log in

Brain cancer in 2012

Molecular characterization leads the way

  • Year in Review
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

In 2012, advances in molecular profiling of primary brain tumours allowed identification of subgroups of glioma and medulloblastoma that were associated with distinct prognoses and predicted treatment response. Adjuvant chemotherapy is now established for 1p/19q co-deleted anaplastic oligodendrogliomas, and may be the preferred treatment in elderly patients with glioblastoma with a methylated MGMT promoter.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Wick, W. et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 13, 707–715 (2012).

    Article  CAS  Google Scholar 

  2. Malmström, A. et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 13, 916–926 (2012).

    Article  Google Scholar 

  3. van den Bent, M. J. et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2012.43.2229.

  4. Shaw, E. G. et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J. Clin. Oncol. 30, 3065–3070 (2012).

    Article  CAS  Google Scholar 

  5. Chinot, O. et al. Roche study showed that Avastin helped people with newly diagnosed gliobastoma live longer without their disease worsening when added to radiation and chemotherapy. F. Hoffmann-La Roche Ltd, [online] (2012).

  6. Stupp, R. et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur. J. Cancer 48, 2192–2202 (2012).

    Article  Google Scholar 

  7. Choi, C. et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat. Med. 18, 624–629 (2012).

    Article  CAS  Google Scholar 

  8. Northcott, P. A., Korshunov, A., Pfister, S. M. & Taylor, M. D. The clinical implications of medulloblastoma subgroups. Nat. Rev. Neurol. 8, 340–351 (2012).

    Article  CAS  Google Scholar 

  9. Robinson, G. et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 488, 43–48 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Neurosurgery, Department of Clinical Neurosciences, University of Lausanne Hospital (CHUV), 46 Rue du Bugnon, Lausanne, 1011, Switzerland

    Roger Stupp & Monika E. Hegi

Authors
  1. Roger Stupp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monika E. Hegi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roger Stupp.

Ethics declarations

Competing interests

R. Stupp served on Advisory Boards to MSD (Merck & Co.), Merck Serono (EMD), and Roche. He is the principal investigator of phase III trials investigating Cilengitide (Merck Serono) and the NovoTTF device (NovoCure Ltd) in glioblastoma. M. E. Hegi served on Advisory Boards to MSD (Merck & Co.), Merck Serono (EMD), and MDxHealth.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stupp, R., Hegi, M. Molecular characterization leads the way. Nat Rev Clin Oncol 10, 69–70 (2013). https://doi.org/10.1038/nrclinonc.2012.240

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2012.240

  • Springer Nature Limited

Search

Navigation